Abstract
Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anti-cancer therapy. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activity has been identified in several cancers. In particular, imbalance in histone acetylation can lead to changes in chromatin structure and transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and/or apoptosis. In addition, several non histone protein substrates such as transcription factors, chaperone proteins or tubulin, undergo acetylation as key post-translation modification regulating their half-life and function. On this regard, several inhibitors of HDAC, selected by academic as well as industrial research, have been recently shown to induce growth arrest and apoptosis in a variety of human cancer cells and have been patented as anti-cancer agents. Although several clinical studies with HDAC inhibitors are ongoing, their mechanism of action cannot be solely attributed to the level of histone acetylation and molecular basis for their tumor selectivity remains unknown, presenting a challenge for the cancer research community.
Keywords: Histone deacetylase, histone deacetylase inhibitors, combination therapy, cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Volume: 2 Issue: 2
Author(s): Alfredo Budillon, Elena Di Gennaro, Francesca Bruzzese, Monia Rocco, Giuseppe Manzo and Michele Caraglia
Affiliation:
Keywords: Histone deacetylase, histone deacetylase inhibitors, combination therapy, cancer
Abstract: Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anti-cancer therapy. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activity has been identified in several cancers. In particular, imbalance in histone acetylation can lead to changes in chromatin structure and transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and/or apoptosis. In addition, several non histone protein substrates such as transcription factors, chaperone proteins or tubulin, undergo acetylation as key post-translation modification regulating their half-life and function. On this regard, several inhibitors of HDAC, selected by academic as well as industrial research, have been recently shown to induce growth arrest and apoptosis in a variety of human cancer cells and have been patented as anti-cancer agents. Although several clinical studies with HDAC inhibitors are ongoing, their mechanism of action cannot be solely attributed to the level of histone acetylation and molecular basis for their tumor selectivity remains unknown, presenting a challenge for the cancer research community.
Export Options
About this article
Cite this article as:
Alfredo Budillon , Elena Di Gennaro , Francesca Bruzzese , Monia Rocco , Giuseppe Manzo and Michele Caraglia , Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (2) . https://dx.doi.org/10.2174/157489207780832450
DOI https://dx.doi.org/10.2174/157489207780832450 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Review on Molecular Mechanism of Hypertensive Nephropathy
Current Pharmaceutical Design Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer
Current Pharmaceutical Design The Comparison of Periostin Levels in Gingival Crevicular Fluid among Patients with Endometrial Cancer and Chronic Periodontitis
Current Women`s Health Reviews Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Strategies for Leukotriene Modulation in Dermatology: Even More Visionary Perspectives? An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration through the Transcription Factor E2F1 in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review
Current Medicinal Chemistry Chemical and Biological Approaches for Mycotoxin Control: A Review
Recent Patents on Food, Nutrition & Agriculture Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Photodynamic Inactivation of Bacteria
Current Bioactive Compounds Exploiting Significance of Physical Exercise in Prevention of Gastrointestinal Disorders
Current Pharmaceutical Design Preface [Hot topic: Implications of COX-2 Inhibition in the Gastrointestinal Tract (Executive Editor : Angel Lanas)]
Current Pharmaceutical Design